The infusion rate should be reduced by 50% in case of nonserious infusion reactions In patients who develop serious infusion reactions, cetuximab should be discontinued immediately and permanently ...
Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...
Cetuximab is used to treat a certain type of cancer of the colon (large intestine) or rectum. This medication is also used to treat head and neck cancer. Nausea, vomiting, constipation ...
Cetuximab is a monoclonal antibody with activity against colorectal cancers that overexpress epidermal growth factor receptor. This agent blocks epidermal growth factor receptor signaling and ...
SAN DIEGO – A combination of the KRAS G12C inhibitor adagrasib (Krazati) and the anti-epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux) showed clinical activity and promising ...
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC ...
May 3, 2024 Cardiff Oncology, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter ...
Disease control was observed in 85% of patients. With a median follow-up of 11.9 months in 94 patients, Krazati plus cetuximab demonstrated an objective response rate, the primary endpoint ...
Review the side-effects of Cetuximab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...
The results showed objective responses in 32 of 94 patients treated with the KRAS inhibitor adagrasib (Krazati) and the EGFR inhibitor cetuximab (Erbitux). An additional 48 patients had stable ...
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback